Phase 2 trials of VTX958 are ongoing in plaque psoriasis, Crohn’s disease and psoriatic arthritis, with topline data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 in. | May 11, 2023
Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) CEO Raju Mohan sold 30,000 shares of Ventyx Biosciences stock in a transaction dated Friday, May 5th. The shares were sold at an average price of $39.28, for a total value of $1,178,400.00. Following the sale, the chief executive officer now owns 1,543,126 shares of the company’s stock, […]
Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) CEO Raju Mohan sold 30,000 shares of the business’s stock in a transaction dated Friday, May 5th. The shares were sold at an average price of $39.28, for a total value of $1,178,400.00. Following the completion of the sale, the chief executive officer now directly owns 1,543,126 shares […]
Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) have earned an average rating of “Buy” from the ten research firms that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have updated their coverage on the […]
Ventyx Biosciences, Inc. (NASDAQ:VTYX – Get Rating) CEO Raju Mohan sold 9,255 shares of the stock in a transaction that occurred on Monday, April 10th. The stock was sold at an average price of $29.01, for a total value of $268,487.55. Following the completion of the sale, the chief executive officer now directly owns 1,573,126 […]